Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04504825




Registration number
NCT04504825
Ethics application status
Date submitted
20/07/2020
Date registered
7/08/2020
Date last updated
30/11/2023

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
Scientific title
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis
Secondary ID [1] 0 0
CAEL101-301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
AL Amyloidosis 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Blood 0 0 0 0
Other blood disorders
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CAEL-101
Other interventions - Placebo
Treatment: Drugs - cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen

Experimental: CAEL-101 combined with SoC plasma cell dyscrasia - CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. The study is divided into 2 parts, the Primary Evaluation Treatment period part and the Open-Label Extension period of Study.

Placebo Comparator: Placebo combined with SoC plasma cell dyscrasia - Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment.


Treatment: Drugs: CAEL-101
The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.

Other interventions: Placebo
Commercially available 0.9% Normal Saline will be used as the placebo.

Treatment: Drugs: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
According to institutional standard of care.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to All-cause Mortality or to the end of the PETP
Timepoint [1] 0 0
Up to week 52
Primary outcome [2] 0 0
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Timepoint [2] 0 0
Up to week 52
Secondary outcome [1] 0 0
Change from Baseline to week 50 in the Kansas City Cardiomyopathy Questionnaire-Overall Score (KCCQ-OS)
Timepoint [1] 0 0
Baseline, Week 50
Secondary outcome [2] 0 0
Change from Baseline to Week 50 in Cardiac Improvement by Global Longitudinal Strain (GLS%)
Timepoint [2] 0 0
Baseline, Week 50
Secondary outcome [3] 0 0
Change from Baseline to Week 50 in distance walked (in meters) during a six-minute walk test (6MWT)
Timepoint [3] 0 0
Baseline, Week 50
Secondary outcome [4] 0 0
Change from Baseline to Week 50 the Short Form-36 (SF-36) v2 Physical Component Score (PCS)
Timepoint [4] 0 0
Baseline, Week 50

Eligibility
Key inclusion criteria
Key

- AL amyloidosis stage IIIb based on the European Modification of the 2004 Standard Mayo
Clinic Staging (NT-proBNP > 8,500 ng/L) at the time of Screening

- Measurable hematologic disease at Screening as defined by at least one of the
following:

1. Involved/uninvolved free light chain difference (dFLC) > 4 mg/dL or

2. Involved free light chain (iFLC) > 4 mg/dL with abnormal Kappa/Lambda ratio or

3. Serum protein electrophoresis (SPEP) m-spike > 0.5 g/dL

- Histopathological diagnosis of amyloidosis based on polarizing light microscopy of
green bi-refringent material in Congo red stained tissue specimens AND confirmation of
AL derived amyloid deposits by at least one of the following:

1. Immunohistochemistry/Immunofluorescence or

2. Mass spectrometry or

3. Characteristic electron microscopy appearance/Immunoelectron microscopy

- Cardiac involvement as defined by:

1. Documented clinical signs and symptoms supportive of a diagnosis of heart failure
in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an
alternative explanation for heart failure AND

2. At least one of the following:

i. Endomyocardial biopsy demonstrating AL cardiac amyloidosis or ii. Echocardiogram
demonstrating a mean left ventricular wall thickness (calculated as [IVSd+LPWd]/2) of
> 12 mm at diastole in the absence of other causes (e.g., severe hypertension, aortic
stenosis), which would adequately explain the degree of wall thickening or iii.
Cardiac magnetic resonance imaging (MRI) with gadolinium contrast agent diagnostic of
cardiac amyloidosis

- Planned first-line treatment for plasma cell dyscrasia is
cyclophosphamide-bortezomib-dexamethasone (CyBorD)-based regimen administered as SoC

- Women of childbearing potential (WOCBP) must have a negative pregnancy test during
Screening and must agree to use highly effective contraception from Screening to at
least 5 months following the last study drug administration or 12 months following the
last dose of her PCD therapy, whichever is longer

- Men must be surgically sterile or must agree to use highly effective contraception and
refrain from donating sperm from Screening to at least 5 months following the last
study drug administration or 12 months following the last dose of their PCD therapy,
whichever is longer

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Have any other form of amyloidosis other than AL amyloidosis

- Received prior therapy for AL amyloidosis or multiple myeloma. A maximum exposure of 2
weeks of a CyBorD-based PCD treatment after Screening laboratory samples are obtained
and prior to randomization is allowed

- Has POEMS (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy,
monoclonal protein and skin changes) syndrome or multiple myeloma defined as clonal
bone marrow plasma cells > 10% from a bone marrow biopsy (performed = 3 months prior
to signing the ICF) or biopsy-proven (performed = 3 months prior to signing the ICF)
bony or extramedullary plasmacytoma AND one or more of the following CRAB features:

a. Evidence of end organ damage that can be attributed to the underlying plasma cell
proliferative disorder (e.g., multiple myeloma and POEMS syndrome), specifically: i.
Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the ULN or > 2.75
mmol/L (> 11 mg/dL) OR ii. Renal insufficiency: creatinine clearance < 40 mL per
minute or serum creatinine > 177 mol/L (> 2 mg/dL) OR iii. Anemia: hemoglobin value of
> 20 g/L below the lowest limit of normal, or a hemoglobin value < 100 g/L OR iv. Bone
lesions: one or more osteolytic lesion on imaging tests (performed = 3 months prior to
signing the ICF): skeletal radiography, CT, or PET/CT, or MRI. If bone marrow has <
10% clonal plasma cells, more than one bone lesion is required to distinguish from
solitary plasmacytoma with minimal marrow involvement OR b. Any one of the following
biomarkers of malignancy: i. 60% or greater clonal plasma cells on bone marrow
examination OR ii. More than one focal lesion on MRI that is at least 5mm or greater
in size

- Have supine systolic blood pressure < 90 mmHg or symptomatic orthostatic hypotension,
defined as a decrease in systolic blood pressure upon standing of > 30 mmHg despite
medical management (e.g., midodrine, fludrocortisones) in the absence of volume
depletion

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/02/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
14/12/2026
Actual
Sample size
Target
124
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Clinical Trial Site - Adelaide
Recruitment hospital [2] 0 0
Clinical Trial Site - Brisbane
Recruitment hospital [3] 0 0
Clinical Trial Site - Murdoch
Recruitment hospital [4] 0 0
Clinical Trial Site - Sydney
Recruitment postcode(s) [1] 0 0
SA 5000 - Adelaide
Recruitment postcode(s) [2] 0 0
QLD 4102 - Brisbane
Recruitment postcode(s) [3] 0 0
WA 6150 - Murdoch
Recruitment postcode(s) [4] 0 0
NSW 2145 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Utah
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
United States of America
State/province [20] 0 0
Wisconsin
Country [21] 0 0
Austria
State/province [21] 0 0
Linz
Country [22] 0 0
Belgium
State/province [22] 0 0
Bruxelles
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Brazil
State/province [24] 0 0
Porto Alegre
Country [25] 0 0
Brazil
State/province [25] 0 0
Recife
Country [26] 0 0
Brazil
State/province [26] 0 0
Ribeirao Preto
Country [27] 0 0
Brazil
State/province [27] 0 0
Santo Amaro
Country [28] 0 0
Brazil
State/province [28] 0 0
Sao Paulo
Country [29] 0 0
Brazil
State/province [29] 0 0
São José do Rio Preto
Country [30] 0 0
Brazil
State/province [30] 0 0
São Paulo
Country [31] 0 0
Canada
State/province [31] 0 0
Alberta
Country [32] 0 0
Canada
State/province [32] 0 0
Ontario
Country [33] 0 0
China
State/province [33] 0 0
Beijing
Country [34] 0 0
China
State/province [34] 0 0
Guangzhou
Country [35] 0 0
China
State/province [35] 0 0
Hangzhou
Country [36] 0 0
China
State/province [36] 0 0
Shanghai
Country [37] 0 0
China
State/province [37] 0 0
Suzhou
Country [38] 0 0
China
State/province [38] 0 0
Wenzhou
Country [39] 0 0
China
State/province [39] 0 0
Wuhan
Country [40] 0 0
Czechia
State/province [40] 0 0
Ostrava
Country [41] 0 0
France
State/province [41] 0 0
Caen
Country [42] 0 0
France
State/province [42] 0 0
Créteil
Country [43] 0 0
France
State/province [43] 0 0
Dijon
Country [44] 0 0
France
State/province [44] 0 0
Lille
Country [45] 0 0
France
State/province [45] 0 0
Limoges
Country [46] 0 0
France
State/province [46] 0 0
Marseille
Country [47] 0 0
France
State/province [47] 0 0
Paris
Country [48] 0 0
France
State/province [48] 0 0
Pessac
Country [49] 0 0
France
State/province [49] 0 0
Pierre-Bénite
Country [50] 0 0
France
State/province [50] 0 0
Poitiers
Country [51] 0 0
France
State/province [51] 0 0
Rennes
Country [52] 0 0
France
State/province [52] 0 0
Toulouse
Country [53] 0 0
France
State/province [53] 0 0
Tours
Country [54] 0 0
Germany
State/province [54] 0 0
Berlin
Country [55] 0 0
Germany
State/province [55] 0 0
Düsseldorf
Country [56] 0 0
Germany
State/province [56] 0 0
Essen
Country [57] 0 0
Germany
State/province [57] 0 0
Hamburg
Country [58] 0 0
Germany
State/province [58] 0 0
Heidelberg
Country [59] 0 0
Germany
State/province [59] 0 0
Würzburg
Country [60] 0 0
Greece
State/province [60] 0 0
Athens
Country [61] 0 0
Greece
State/province [61] 0 0
Patras
Country [62] 0 0
Greece
State/province [62] 0 0
Thessaloníki
Country [63] 0 0
Israel
State/province [63] 0 0
Haifa
Country [64] 0 0
Israel
State/province [64] 0 0
Jerusalem
Country [65] 0 0
Israel
State/province [65] 0 0
Petah Tikva
Country [66] 0 0
Israel
State/province [66] 0 0
Ramat Gan
Country [67] 0 0
Israel
State/province [67] 0 0
Tel Aviv
Country [68] 0 0
Italy
State/province [68] 0 0
Brescia
Country [69] 0 0
Italy
State/province [69] 0 0
Naples
Country [70] 0 0
Italy
State/province [70] 0 0
Pavia
Country [71] 0 0
Italy
State/province [71] 0 0
Rome
Country [72] 0 0
Japan
State/province [72] 0 0
Kumamoto
Country [73] 0 0
Japan
State/province [73] 0 0
Fukushima
Country [74] 0 0
Japan
State/province [74] 0 0
Nagoya
Country [75] 0 0
Japan
State/province [75] 0 0
Tokyo
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Seoul
Country [77] 0 0
Netherlands
State/province [77] 0 0
Amsterdam
Country [78] 0 0
Netherlands
State/province [78] 0 0
Groningen
Country [79] 0 0
Netherlands
State/province [79] 0 0
Utrecht
Country [80] 0 0
Poland
State/province [80] 0 0
Gdansk
Country [81] 0 0
Poland
State/province [81] 0 0
Poznan
Country [82] 0 0
Poland
State/province [82] 0 0
Warszawa
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Moscow
Country [84] 0 0
Russian Federation
State/province [84] 0 0
Saint Petersburg
Country [85] 0 0
Spain
State/province [85] 0 0
Barcelona
Country [86] 0 0
Spain
State/province [86] 0 0
Gijon
Country [87] 0 0
Spain
State/province [87] 0 0
Granada
Country [88] 0 0
Spain
State/province [88] 0 0
Madrid
Country [89] 0 0
Spain
State/province [89] 0 0
Pamplona
Country [90] 0 0
Spain
State/province [90] 0 0
Salamanca
Country [91] 0 0
Spain
State/province [91] 0 0
Sevilla
Country [92] 0 0
Spain
State/province [92] 0 0
Valencia
Country [93] 0 0
Switzerland
State/province [93] 0 0
Bern
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Glasgow
Country [95] 0 0
United Kingdom
State/province [95] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Alexion Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and
create free light chains that cannot be broken down. These free light chains bind together to
form amyloid fibrils that build up in the extracellular space of organs, affecting the
kidneys, heart, liver, spleen, nervous system and digestive tract.

The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody
that removes AL amyloid deposits from tissues and organs, improves overall survival and it is
safe and well tolerated in patients with stage IIIb AL amyloidosis.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04504825
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Scott Swenson, MD
Address 0 0
Alexion, AstraZeneca Rare Disease
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04504825